ACHL vs. TIL, IVVD, TVGN, CMPX, XFOR, AGEN, OPT, VXRT, ATHA, and BLUE
Should you be buying Achilles Therapeutics stock or one of its competitors? The main competitors of Achilles Therapeutics include Instil Bio (TIL), Invivyd (IVVD), Tevogen Bio (TVGN), Compass Therapeutics (CMPX), X4 Pharmaceuticals (XFOR), Agenus (AGEN), Opthea (OPT), Vaxart (VXRT), Athira Pharma (ATHA), and bluebird bio (BLUE). These companies are all part of the "biological products, except diagnostic" industry.
Achilles Therapeutics (NASDAQ:ACHL) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.
In the previous week, Achilles Therapeutics had 1 more articles in the media than Instil Bio. MarketBeat recorded 3 mentions for Achilles Therapeutics and 2 mentions for Instil Bio. Achilles Therapeutics' average media sentiment score of 1.44 beat Instil Bio's score of 0.53 indicating that Achilles Therapeutics is being referred to more favorably in the media.
Achilles Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 382.57%. Instil Bio has a consensus price target of $25.00, indicating a potential upside of 99.52%. Given Achilles Therapeutics' higher possible upside, research analysts clearly believe Achilles Therapeutics is more favorable than Instil Bio.
Instil Bio is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.
56.4% of Achilles Therapeutics shares are owned by institutional investors. Comparatively, 60.6% of Instil Bio shares are owned by institutional investors. 5.4% of Achilles Therapeutics shares are owned by insiders. Comparatively, 46.5% of Instil Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Achilles Therapeutics' return on equity of -42.95% beat Instil Bio's return on equity.
Achilles Therapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Instil Bio has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500.
Instil Bio received 77 more outperform votes than Achilles Therapeutics when rated by MarketBeat users. However, 54.84% of users gave Achilles Therapeutics an outperform vote while only 51.09% of users gave Instil Bio an outperform vote.
Summary
Achilles Therapeutics beats Instil Bio on 9 of the 15 factors compared between the two stocks.
Get Achilles Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACHL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Achilles Therapeutics Competitors List
Related Companies and Tools
Free ACHL Stock Alerts